<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01374880</url>
  </required_header>
  <id_info>
    <org_study_id>CNIL number: 910198</org_study_id>
    <secondary_id>Unité 942 INSERM</secondary_id>
    <nct_id>NCT01374880</nct_id>
  </id_info>
  <brief_title>Diagnostic and Prognostic Value of New Biomarkers in Patients With Heart Disease</brief_title>
  <official_title>Diagnostic and Prognostic Value of New Biomarkers in Patients With Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Paris 7 - Denis Diderot</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ThermoFisher Scientific Brahms Biomarkers France</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alere San Diego</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Servier</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Laboratory Medicine, Konventhospital Barmherzige Brueder, Linz, Austria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Virgen de la Arrixaca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Monastir, Tunis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Università degli Studi di Brescia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Intensive and Cardiac Care Unit, Nippon Medical School, Tokyo, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brno University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this work is to investigate and then to sequence new biomarkers in the
      plasma of patients presenting with dyspnea secondary or not to heart failure, and study their
      diagnostic and prognostic value.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Plasma samples for patients with dyspnea, edema, with or without heart failure; ambulatory or
      admitted for cardiac decompensation (even with cardiac shock and LVAD) ; or entering a
      cardiac rehabilitation program, will be prospectively collected.

      The objective of this work is to investigate and then to sequence new proteins in the plasma
      of these patients for diagnostic and prognostic purpose.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Long term cardiovascular mortality</measure>
    <time_frame>Prospective at 12 months</time_frame>
    <description>To detect prognostic values of plasma biomarkers, we assess cardiovascular mortality at 3, 6, and 24 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac hospitalization(s) at 3, 6,12 and 24 months</measure>
    <time_frame>Prospective at 12 months</time_frame>
    <description>We assess cardiac morbidity within 3, 6, and 24 months months after admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic value of new biomarkers.</measure>
    <time_frame>at day 0</time_frame>
    <description>Assess accuracy of new biomarkers to discriminate heart failure from non-heart failure (negative and positive predictive values)</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Heart Failure</condition>
  <condition>Dyspnea</condition>
  <condition>Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Dyspnea cohort</arm_group_label>
    <description>Dyspnea cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stable chronic heart failure</arm_group_label>
    <description>Stable chronic heart failure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valvular heart disease</arm_group_label>
    <description>Valvular heart disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ventricular assist device</arm_group_label>
    <description>Ventricular assist device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cardiac arrest</arm_group_label>
    <description>Cardiac arrest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cardiac rehabilitation</arm_group_label>
    <description>Cardiac rehabilitation</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biomarkers assessment in plasma at different times according to the study cohort.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting with dyspnea secondary or not to heart failure. Patients with dyspnea,
        edema, with heart failure, ambulatory or admitted for cardiac decompensation (even with
        cardiac shock and LVAD) ; or entering a cardiac rehabilitation program, will be
        prospectively collected.

        Patients with valvular disease or with chronic heart failure.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting with shortness of breath secondary or not to heart failure, even
             with cardiac shock and LVAD.

          -  Patients with valvular disease

          -  chronic stable heart failure.

          -  post- partum Cardiomyopathy

        Exclusion Criteria:

          -  terminal cancer

          -  progressive neurological disease

          -  pregnancy

          -  opposition of the patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Cohen-Solal, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre Mebazaa, PHD</last_name>
    <phone>+33(0)149958071</phone>
    <email>alexandre.mebazaa@lrb.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alain Cohen-Solal, PHD</last_name>
    <phone>+33(0)149956608</phone>
    <email>alain.cohen-solal@lrb.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lariboisiere hospital</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Said Laribi, MD</last_name>
      <phone>+33(0)149956445</phone>
      <email>said.laribi@lrb.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2011</study_first_submitted>
  <study_first_submitted_qc>June 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2011</study_first_posted>
  <last_update_submitted>August 13, 2013</last_update_submitted>
  <last_update_submitted_qc>August 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Dyspnea</keyword>
  <keyword>Heart disease</keyword>
  <keyword>Pulmonary disease</keyword>
  <keyword>Natriuretic peptide</keyword>
  <keyword>Rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

